- Bandeiras C, Cabral JMS, Gabbay RA, Finkelstein SN, Ferreira FC. Bringing stem cell-based therapies for type 1 diabetes to the clinic: early insights from bioprocess economics and cost-effectiveness analysis. Biotechnology journal. 2019:e1800563.
- Hannouf MB, Zaric GS, Blanchette P, Brezden-Masley C, Paulden M, McCabe C, et al. Cost-effectiveness analysis of multigene expression profiling assays to guide adjuvant therapy decisions in women with invasive early-stage breast cancer. The pharmacogenomics journal. 2019.
- Love-Koh J, Cookson R, Gutacker N, Patton T, Griffin S. Aggregate Distributional Cost-Effectiveness Analysis of Health Technologies. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2019;22(5):518-26.
- Sawaya GF, Sanstead E, Alarid-Escudero F, Smith-McCune K, Gregorich SE, Silverberg MJ, et al. Estimated Quality of Life and Economic Outcomes Associated With 12 Cervical Cancer Screening Strategies: A Cost-effectiveness Analysis. JAMA internal medicine. 2019.
- Shaker M, Greenhawt M. Estimation of Health and Economic Benefits of Commercial Peanut Immunotherapy Products: A Cost-effectiveness Analysis. JAMA network open. 2019;2(5):e193242.
HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.
Thursday 20 June 2019
May’s CEAs.....
We’ve completed our quick search for CEA’s published last month. In the right-hand column of this blog is a CEA Archive of all records. Below are those in our areas of interest.